SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001564590-20-017939
Filing Date
2020-04-22
Accepted
2020-04-22 16:35:15
Documents
5
Effectiveness Date
2020-04-22

Document Format Files

Seq Description Document Type Size
1 DEFA14A atra-defa14a_20200616.htm DEFA14A 33380
2 GRAPHIC gfrmmuaex4db000001.jpg GRAPHIC 39012
3 GRAPHIC gfrmmuaex4db000002.jpg GRAPHIC 61999
4 GRAPHIC gfrmmuaex4db000004.jpg GRAPHIC 11175
5 GRAPHIC gfrmmuaex4db000003.jpg GRAPHIC 20353
  Complete submission text file 0001564590-20-017939.txt   217480
Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36548 | Film No.: 20808267
SIC: 2836 Biological Products, (No Diagnostic Substances)